Literature DB >> 17936561

FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia.

Benjamin H Lee1, Zuzana Tothova, Ross L Levine, Kristina Anderson, Natalija Buza-Vidas, Dana E Cullen, Elizabeth P McDowell, Jennifer Adelsperger, Stefan Fröhling, Brian J P Huntly, Miloslav Beran, Sten Eirik Jacobsen, D Gary Gilliland.   

Abstract

Despite their known transforming properties, the effects of leukemogenic FLT3-ITD mutations on hematopoietic stem and multipotent progenitor cells and on hematopoietic differentiation are not well understood. We report a mouse model harboring an ITD in the murine Flt3 locus that develops myeloproliferative disease resembling CMML and further identified FLT3-ITD mutations in a subset of human CMML. These findings correlated with an increase in number, cell cycling, and survival of multipotent stem and progenitor cells in an ITD dose-dependent manner in animals that exhibited alterations within their myeloid progenitor compartments and a block in normal B cell development. This model provides insights into the consequences of constitutive signaling by an oncogenic tyrosine kinase on hematopoietic progenitor quiescence, function, and cell fate.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17936561      PMCID: PMC2104473          DOI: 10.1016/j.ccr.2007.08.031

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  60 in total

1.  Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways.

Authors:  M Mizuki; R Fenski; H Halfter; I Matsumura; R Schmidt; C Müller; W Grüning; K Kratz-Albers; S Serve; C Steur; T Büchner; J Kienast; Y Kanakura; W E Berdel; H Serve
Journal:  Blood       Date:  2000-12-01       Impact factor: 22.113

2.  FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model.

Authors:  Rebekka Grundler; Cornelius Miething; Christian Thiede; Christian Peschel; Justus Duyster
Journal:  Blood       Date:  2005-02-17       Impact factor: 22.113

3.  MOZ-TIF2-induced acute myeloid leukemia requires the MOZ nucleosome binding motif and TIF2-mediated recruitment of CBP.

Authors:  Kenji Deguchi; Paul M Ayton; Melina Carapeti; Jeffery L Kutok; Cynthia S Snyder; Ifor R Williams; Nicholas C P Cross; Christopher K Glass; Michael L Cleary; D Gary Gilliland
Journal:  Cancer Cell       Date:  2003-03       Impact factor: 31.743

4.  Expression of the FLT3 gene in human leukemia-lymphoma cell lines.

Authors:  N DaSilva; Z B Hu; W Ma; O Rosnet; D Birnbaum; H G Drexler
Journal:  Leukemia       Date:  1994-05       Impact factor: 11.528

5.  Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders.

Authors:  Marianna David; Nicholas C P Cross; Sonja Burgstaller; Andrew Chase; Claire Curtis; Raymond Dang; Martine Gardembas; John M Goldman; Francis Grand; George Hughes; Francoise Huguet; Louise Lavender; Grant A McArthur; Francois X Mahon; Giorgio Massimini; Junia Melo; Philippe Rousselot; Robin J Russell-Jones; John F Seymour; Graeme Smith; Alastair Stark; Katherine Waghorn; Zariana Nikolova; Jane F Apperley
Journal:  Blood       Date:  2006-09-07       Impact factor: 22.113

6.  The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials.

Authors:  P D Kottaridis; R E Gale; M E Frew; G Harrison; S E Langabeer; A A Belton; H Walker; K Wheatley; D T Bowen; A K Burnett; A H Goldstone; D C Linch
Journal:  Blood       Date:  2001-09-15       Impact factor: 22.113

7.  FLT3/FLK-2 (STK-1) Ligand does not stimulate human megakaryopoiesis in vitro.

Authors:  M Z Ratajczak; J Ratajczak; J Ford; R Kregenow; W Marlicz; A M Gewirtz
Journal:  Stem Cells       Date:  1996-01       Impact factor: 6.277

8.  Prognostic factors in adult chronic myelomonocytic leukemia: an analysis of 107 cases.

Authors:  P Fenaux; R Beuscart; J L Lai; J P Jouet; F Bauters
Journal:  J Clin Oncol       Date:  1988-09       Impact factor: 44.544

9.  The flt3/flk-2 ligand: receptor distribution and action on murine haemopoietic cell survival and proliferation.

Authors:  J E Rasko; D Metcalf; M T Rossner; C G Begley; N A Nicola
Journal:  Leukemia       Date:  1995-12       Impact factor: 11.528

10.  Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors.

Authors:  K Mackarehtschian; J D Hardin; K A Moore; S Boast; S P Goff; I R Lemischka
Journal:  Immunity       Date:  1995-07       Impact factor: 31.745

View more
  100 in total

1.  Loss of DEP-1 (Ptprj) promotes myeloproliferative disease in FLT3-ITD acute myeloid leukemia.

Authors:  Anne Kresinsky; Reinhard Bauer; Tina M Schnöder; Tobias Berg; Daria Meyer; Volker Ast; Rainer König; Hubert Serve; Florian H Heidel; Frank-D Böhmer; Jörg P Müller
Journal:  Haematologica       Date:  2018-06-07       Impact factor: 9.941

2.  Persistence of leukemia-initiating cells in a conditional knockin model of an imatinib-responsive myeloproliferative disorder.

Authors:  Katherine I Oravecz-Wilson; Steven T Philips; Omer H Yilmaz; Heather M Ames; Lina Li; Brendan D Crawford; Alice M Gauvin; Peter C Lucas; Kajal Sitwala; James R Downing; Sean J Morrison; Theodora S Ross
Journal:  Cancer Cell       Date:  2009-08-04       Impact factor: 31.743

3.  Acquired isodisomy on chromosome 13 at diagnosis results in impaired overall survival in patients with FLT3-ITD mutant acute myeloid leukaemia.

Authors:  J C T Loke; S Akiki; J Borrow; J Ewing; S W Bokhari; D Chandra; J Arrazi; P Hazlewood; K Arthur; J Walsh; Y Membwange; F A Wandroo; A Watts; A Borg; K Brock; P Ferguson; C Craddock; M Griffiths; M Raghavan
Journal:  Leukemia       Date:  2015-06-19       Impact factor: 11.528

4.  RNA binding protein MSI2 positively regulates FLT3 expression in myeloid leukemia.

Authors:  Ayuna Hattori; Daniel McSkimming; Natarajan Kannan; Takahiro Ito
Journal:  Leuk Res       Date:  2017-01-11       Impact factor: 3.156

5.  NFATc1 as a therapeutic target in FLT3-ITD-positive AML.

Authors:  S K Metzelder; C Michel; M von Bonin; M Rehberger; E Hessmann; S Inselmann; M Solovey; Y Wang; K Sohlbach; C Brendel; T Stiewe; J Charles; A Ten Haaf; V Ellenrieder; A Neubauer; S Gattenlöhner; M Bornhäuser; A Burchert
Journal:  Leukemia       Date:  2015-04-14       Impact factor: 11.528

6.  STAT5 is crucial to maintain leukemic stem cells in acute myelogenous leukemias induced by MOZ-TIF2.

Authors:  Winnie F Tam; Patricia S Hähnel; Andrea Schüler; Benjamin H Lee; Rachel Okabe; Nan Zhu; Saskia V Pante; Glen Raffel; Thomas Mercher; Gerlinde Wernig; Ernesto Bockamp; Daniel Sasca; Andreas Kreft; Gertraud W Robinson; Lothar Hennighausen; D Gary Gilliland; Thomas Kindler
Journal:  Cancer Res       Date:  2012-11-13       Impact factor: 12.701

7.  FLT3-ITD impedes retinoic acid, but not arsenic, responses in murine acute promyelocytic leukemias.

Authors:  Cécile Esnault; Ramy Rahmé; Kim L Rice; Caroline Berthier; Coline Gaillard; Samuel Quentin; Anne-Lise Maubert; Scott Kogan; Hugues de Thé
Journal:  Blood       Date:  2019-01-23       Impact factor: 22.113

8.  miR-155 promotes FLT3-ITD-induced myeloproliferative disease through inhibition of the interferon response.

Authors:  Jared A Wallace; Dominique A Kagele; Anna M Eiring; Carissa N Kim; Ruozhen Hu; Marah C Runtsch; Margaret Alexander; Thomas B Huffaker; Soh-Hyun Lee; Ami B Patel; Timothy L Mosbruger; Warren P Voth; Dinesh S Rao; Rodney R Miles; June L Round; Michael W Deininger; Ryan M O'Connell
Journal:  Blood       Date:  2017-04-21       Impact factor: 22.113

Review 9.  Engineering mouse models with myelodysplastic syndrome human candidate genes; how relevant are they?

Authors:  Stephanie Beurlet; Christine Chomienne; Rose Ann Padua
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941

10.  Echinomycin protects mice against relapsed acute myeloid leukemia without adverse effect on hematopoietic stem cells.

Authors:  Yin Wang; Yan Liu; Fei Tang; Kelsie M Bernot; Reuven Schore; Guido Marcucci; Michael A Caligiuri; Pan Zheng; Yang Liu
Journal:  Blood       Date:  2014-07-03       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.